Title:
PEPTIDYL NITRILE COMPOUND AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/134656
Kind Code:
A1
Abstract:
Provided are a peptidyl nitrile compound and a use thereof; specifically provided are a compound represented by formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound and/or the pharmaceutically acceptable salt thereof, a method for preparing the compound, and a use of the compound in treating diseases caused by cathepsin C and a downstream serine protease thereof.
Inventors:
YE BIN (CN)
ZHENG MINGFANG (CN)
YAN TAO (CN)
ZHENG MINGFANG (CN)
YAN TAO (CN)
Application Number:
PCT/CN2023/071503
Publication Date:
July 20, 2023
Filing Date:
January 10, 2023
Export Citation:
Assignee:
SHANGHAI YIDIAN PHARMACEUTICAL TECH DEVELOPMENT CO LTD (CN)
International Classes:
A61K31/553; C07D413/10; A61P3/00; A61P9/00; A61P11/00; A61P31/00; A61P35/00; A61P37/00; C07D413/12; C07D417/10; C07D417/12
Domestic Patent References:
| WO2020018551A1 | 2020-01-23 |
Foreign References:
| CN105980367A | 2016-09-28 | |||
| CN109789150A | 2019-05-21 | |||
| US20190247400A1 | 2019-08-15 | |||
| CN112055593A | 2020-12-08 |
Other References:
DOYLE, KEVIN ET AL.: "Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, 2 October 2016 (2016-10-02), XP055600426, DOI: 10.1021/acs.jmedchem.6b01127
Attorney, Agent or Firm:
HFG INTELLECTUAL PROPERTY AGENCY CO., LTD (CN)
Download PDF: